 |
| JUNE
2, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
WEEKLY CEO Q&A:
Robin Toft, CEO, Curebound |
| In
this Q&A, Robin talks about her career
pivot into the nonprofit sector, the
collaborative research model that sets
Curebound apart, the growing role of
philanthropic capital to fill funding
gaps, and what it takes to build both a
high-performing team and a research
accelerator with staying power. More |
|
|
 |
|
One Partner For Your Entire
Vivarium. Research Ready From Day
One. |
|
Learn More
→ |
|
|
- Anixa Biosciences: Strengthens International
Patent Protection for Ovarian Cancer Vaccine
Technology With Canadian Notice of Allowance More
- Genentech: FDA Accepts New Drug Application
for Giredestrant in ER-Positive Early-Stage
Breast Cancer, the First and Only Oral SERD
With Positive Phase III Results in the
Curative Setting More
- Gladstone Institutes: Investigator Andrew
Yang Receives 2026 Sobrato Prize in
Neuroscience More
- GRAIL: Full Results From NHS-Galleri
Trial Demonstrating Substantial Reduction in
Stage IV Cancer Diagnoses at 2026 ASCO
Annual Meeting
More
More*
More*
- GRAIL: PATHFINDER 2 Results of More Than
35,000 Participants Showing the Galleri Test
Substantially Increased Cancer Detection With
Robust Performance and Favorable Safety at
2026 ASCO Annual Meeting More
- HeartBeam: New Peer-Reviewed Article
Demonstrating Potential to Help Identify Heart
Attack Risk at Home More
- IDEAYA Biosciences and Servier: Complete
Data From Phase 2/3 Registrational OptimUM-02
Trial of the Darovasertib Combination in First
Line HLA*A2:01 Negative Metastatic Uveal
Melanoma in a Late-Breaking Oral Presentation
at ASCO More
- Jade Biosciences: Positive Interim Phase 1
Results for JADE101 Demonstrating Potential
Best-in-Class Profile and Every-12-Week Dosing
in IgA Nephropathy
More More
- Personalis: Highlights Early Colorectal
Cancer Recurrence Detection and Ultrasensitive
MRD Performance Across a Broad Set of Tumor
Types at ASCO 2026 More
- Rezolute: Positive Interim Data for Its
Phase 3 upLIFT Study of Ersodetug in Tumor
Hyperinsulinism More
- Sonire Therapeutics: Completes Enrollment in
SUNRISE-I Randomized Controlled Trial of
Ultrasound-Guided HIFU Therapy for Pancreatic
Cancer More
- Veracyte: Commercial Launch of the Prosigna
Breast Test in the U.S. More
- Vera
Therapeutics: Alignment With U.S. FDA on
Earlier ORIGIN Phase 3 Analysis to Support
Potential Full Approval for Atacicept in
Adults With IgA Nephropathy More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Exicure: Receipt of Nasdaq Delinquency
Notice and Filing of Form 10-Q More
- From Seed to Series C: What Investors Look
for Beyond the Science More
- Haisco: Licensing and Research
Collaboration Agreement With Lilly to
Develop Innovative Medicines Across Multiple
Therapeutic Areas More
More*
- More on What's Going On With Summit
Therapeutics Stock on Monday? More
- Top 10 U.S. Biopharma Clusters 2026 More
- Vaxart: Files Definitive Proxy
Statement and Mails Letter to Shareholders
More
|
|
 |
| Biotech’s
most flexible vivarium lab space
to launch and scale studies. |
|
Learn More
→ |
|
|
|
- Big4Bio CEO Weekly Q&A: Robin Toft,
CEO, Curebound More
- How California Built a Global Powerhouse in
Stem Cell and Gene Therapy More
- More on GT Biopharma Seeing Faster
Discovery, Productivity Following AI
Technology Rollout More
- More on a Pioneering Founder Stepping Down
as CEO of His Bay Area Company Ahead of a
Major Test More*
- More on Revolution Medicines’ Daraxonrasib
Doubling Survival in Phase III Pancreatic
Cancer Trial More*
More*
More*
More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
- Telling Your Science Story to
Investors More
- AI in Biotech: The New
Frontier for Leadership & Strategy More
- David Chang to Hand Over the Reins at
Allogene; Ex-Esperion CEO Gets Started at
Phlow More*
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- Hiring Outlook: Job Opportunities on
BioSpace Rise YOY, but Layoffs Affect
Thousands More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: SFBay Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:SFBay,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
